metabolic disease

Ascendis Licences Proprietary Technology to Novo Nordisk

Danish biopharma company Ascendis Pharma will grant pharmaceutical giant Novo Nordisk an exclusive worldwide license to its TransCon technology platform to develop, manufacture, and commercialize proprietary products for the treatment of metabolic and cardiovascular diseases.

News

Pfizer and Wave Life Sciences in Metabolic Diseases Pact

News

AstraZeneca to buy ZS Pharma for $2.7 billion

Top-Feature

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Aenova Holding GmbH

Small Molecules: Choosing a Strategic, Scalable, and De-Risked Development Path

BIO Deutschland e.V.

German Biotech Days 2026: Biotechnology as The Key to Industrial Competitiveness

Expert Insights

Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.